New Uses of Ketamine and Esketamine for Treating Mental Health Disorders
Updated
Abstract
Over the past 25 years, the use of ketamine for psychiatric disorders has expanded significantly.
- Ketamine and its S-enantiomer, esketamine, are increasingly used off-label to manage depression and anxiety.
- Esketamine has received FDA approval specifically for treatment-resistant and suicidal depression.
- Recent research highlights new treatment targets related to ketamine's mechanism of action.
- Emerging evidence suggests ketamine may have potential as a preventive treatment.
- Key limitations and outstanding issues regarding current ketamine treatments are identified.
Simplified
Funding
Competing interests
Dr. Feder has been named coinventor on issued patents, filed by the Icahn School of Medicine at Mount Sinai (ISMMS), related to the use of ketamine as a treatment for posttraumatic stress disorder (PTSD). ISMMS has entered into a licensing agreement related to the development of intranasal ketamine as a treatment for PTSD. As a part of this agreement, ISMMS will receive consideration in the form of royalties, milestones, payments, and equity. As a named coinventor, Dr. Feder is entitled under ISMMS’s intellectual policy to a portion of any consideration received by ISMMS. Dr. Fremont is a named inventor on a pending patent filed by ISMMS for the use of ketamine as a therapy for mild cognitive impairment and dementia. The other authors report no financial relationships with commercial interests.
PubMed